A novel lozenge containing bupivacaine as topical alleviation of oral mucositis pain in patients with head and neck cancer: a pilot study

Keyphrases

• Head-and-neck Cancer 100%
• Bupivacaine 100%
• Pharynx 100%
• Alleviation 100%
• Lozenges 100%
• Oral mucositis 100%
• Oral Cavity 80%
• Adverse Events 40%
• Visual Analog Scale 20%
• Pain Reduction 20%
• Clinically Significant 20%
• Cancer Patients 20%
• Pain Treatment 20%
• Pain Relief 20%
• Single-dose Treatment 20%
• Anesthetic Effect 20%
• Pain Duration 20%
• Long-term Pain 20%
• Patient-assessed 20%
• Mean Reduction 20%
• Oral Pain 20%
• Pain-relieving Effect 20%

Medicine and Dentistry

• Head and Neck Cancer 100%
• Bupivacaine 100%
• Oral Mucositis 100%
• Oral Cavity 80%
• Pharynx 80%
• Adverse Event 40%
• Side Effect 20%
• Visual Analog Scale 20%
• Analgesia 20%
• Single Drug Dose 20%
• Sore Throat 20%
• Mouth Pain 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Head and Neck Cancer 100%
• Bupivacaine 100%
• Oral Mucositis 100%
• Adverse Event 40%
• Side Effect 20%
• Sore Throat 20%
• Mouth Pain 20%